Home/ Stocks/ XCUR

Exicure, Inc. Common Stock

XCUR XNAS

$1.34 +0.05 (+3.70%) ▲ 15-min delayed

Open

$1.35

High

$1.43

Low

$1.27

Volume

40.0K

Market Cap

$8.60M

About Exicure, Inc. Common Stock

Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 8 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-1,828,000	$-0.29
FY 2025	$0	$-4,946,000	$-0.79
Q3 2025	$0	$-2,437,000	$-0.39
Q2 2025	$0	$-2,621,000	$-0.41

Earnings & Analyst Ratings

Next Earnings: Thu, Nov 5, 2026

Calendar →

Related Market News

No specific coverage for XCUR yet. Check out our latest market news or earnings calendar.

Get XCUR Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Exicure, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.